Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2021-07-12 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-07-12 English
Notice of the meeting and record date - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed client brochure or prospectus for redeemable income notes (billets à revenu rachetables) issued by the Bank of Montreal (BMO), linked to the Solactive Canadian Large-Cap 60 AR index. It includes detailed terms and conditions, features of the notes, hypothetical scenarios, coupon payment details, redemption features, and risk factors. The document is not a financial report, earnings release, or regulatory filing but rather a detailed offering document or prospectus for a financial product. It is not an announcement or brief summary but a substantive document describing the product's characteristics and terms. Given the nature of the document as a detailed product brochure/prospectus for a financial instrument issuance, it best fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is 15,000 characters long, indicating it is a full document, not just an announcement or notice. Therefore, the classification is CAP with high confidence.
2021-07-09 English
News release - English.pdf
Regulatory Filings
2021-06-28 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings
2021-06-16 English
Annual MD&A - English.pdf
Regulatory Filings
2021-06-16 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings
2021-06-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.